CryoLife, Inc.

Biomaterials company reports that Q2 revenues increased 12%

Published in Biotech Law Weekly, September 2nd, 2005

CryoLife, Inc., (CRY), a biomaterials and biosurgical-device company, announced that second-quarter revenues of 2005 increased 12% to $17.2 million compared to $15.3 million in the second quarter of 2004.

The net loss in the second quarter of 2005 was $14.4 million or $0.61 per fully diluted common share. Excluding an $11.8 million ($0.49 per common share) charge for settlement of the shareholder class action lawsuit and a $902,000 ($0.04 per common share) noncash charge for the change in the value of the derivative related to the company's 6% convertible preferred stock, the adjusted net loss for the second quarter of 2005 was $1.7 million or $0.08 per fully diluted...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Biotech Law Weekly

Source: Biotech Law Weekly (2005-09-02)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry